HARMONi-2
AK112 in Advanced Non-Small Cell Lung Cancer
- NCT05499390 ↗
- Active, not recruiting
- Akeso
- Deep
We haven't built an HCP commentary report on HARMONi-2 (AK112 and pembrolizumab in Advanced Non-small-cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.
The commentary discusses ivonescimab versus pembrolizumab in first-line PD-L1-positive advanced NSCLC, including the PD-1/VEGF approach and subgroup interpretation. Speakers raise whether pembrolizumab monotherapy is an appropriate comparator for PD-L1-low disease, whether overall survival should be a primary endpoint, and whether findings from the China-only study translate beyond that setting. Discussion also covers control-arm limitations, censoring, toxicity, predictive biomarkers, and whether the data should change practice pending global-trial evidence.
Indexed commentary on HARMONi-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 136 | |
| YouTube | 9 | |
| Podcasts | 6 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Controlled, Multi-center Phase III Clinical Trial of AK112 Versus Pembrolizumab as First-line Treatment for PD-L1-Positive Locally-Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Advanced Non-small-cell Lung Cancer
- Interventions
- AK112; Pembrolizumab
- Arms
- AK112 · Experimental
- Pembrolizumab · Active comparator
- Enrollment
- 398
- Primary outcomes
- PFS assessed by IRRC per RECIST v1.1
- Sponsor
- Akeso
- Start
- Nov 9, 2022
- Primary completion
- Jan 29, 2024
- Results posted
- No
- Registry record
- NCT05499390 · updated Mar 9, 2026
Publications
linked from the registry- Wang L, Yao W, Shen H, Xie C, Chen H, Chen K, Su W, Gan X, Zhuo M, Chen E, Xu Z, Zhang Y, Wang M, Ma R, Wu H, Zhang Z, Ye F, Moore AC, Zhou C. Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1-positive non-small cell lung cancer in the HARMONi-2 study. Future Oncol. 2026 Jan;22(1):27-36. doi: 10.1080/14796694.2025.2601138. Epub 2025 Dec 28. PubMed 41457351
- Xiong A, Wang L, Chen J, Wu L, Liu B, Yao J, Zhong H, Li J, Cheng Y, Sun Y, Ge H, Yao J, Shi Q, Zhou M, Chen B, Han Z, Wang J, Bu Q, Zhao Y, Chen J, Nie L, Li G, Li X, Yu X, Ji Y, Sun D, Ai X, Chu Q, Lin Y, Hao J, Huang D, Zhou C, Shan J, Yang H, Liu X, Wang J, Shang Y, Mei X, Yang J, Lu D, Hu M, Wang ZM, Li B, Xia M, Zhou C. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet. 2025 Mar 8;405(10481):839-849. doi: 10.1016/S0140-6736(24)02722-3. PubMed 40057343